Immunic Plans Phase 3 Progressive MS Trial After Mixed Phase 2 Results
Immunic (NASDAQ: IMUX) plans a Phase 3 trial for vidofludimus calcium in progressive MS after mixed Phase 2 results. The Phase 2 trial missed its primary endpoint but showed encouraging trends in disability outcomes. The company estimates a $18B annual market opportunity for progressive MS treatments.
How this was made

The 30-second read
Why it matters
The mixed Phase 2 data introduces uncertainty about the drug’s efficacy, likely pressuring the stock while keeping some upside potential if Phase 3 succeeds.
Market read
First disclosure of pivotal trial data for a niche MS therapy; impacts IMUX valuation and may influence peer biotech sentiment.
What to watch
Potential market upside if the upcoming Phase 3 trial enrolls a larger cohort and demonstrates clear neuroprotection.
Background
Immunic (NASDAQ:IMUX) is a clinical‑stage biotech developing oral DHODH inhibitors for inflammatory diseases, with vidofludimus calcium as its lead MS candidate.
Ticker impact
Immunic disclosed mixed Phase 2 results for its vidofludimus calcium trial, missing the primary endpoint but showing nominal disability improvement.
likely pressure as investors price in the primary endpoint miss
Phase 2 data is the first public disclosure; missing the key brain‑volume endpoint typically triggers sell‑off, while the nominal p‑value may cushion the drop.
Market effects
May prompt re‑evaluation of other DHODH inhibitors in MS pipelines.
Limited to US‑listed biotech investors.
Modest, confined to niche MS therapeutic space.
Counterpoint
Some investors may view the disability improvement signal as a catalyst for upside if Phase 3 confirms benefit.
Key entities
- companyImmunic, Inc.
US‑listed biotech developing oral therapies for MS.
- productVidofludimus calcium
Lead candidate targeting DHODH for progressive MS.


